Navellier & Associates’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.21M Sell
11,971
-467
-4% -$166K 0.44% 53
2025
Q4
$4.07M Sell
12,438
-1,013
-8% -$321K 0.46% 53
2025
Q3
$3.8M Buy
13,451
+230
+2% +$66.7K 0.39% 71
2025
Q2
$3.69M Sell
13,221
-29
-0.2% -$8.22K 0.46% 62
2025
Q1
$3.71M Sell
13,250
-1,395
-10% -$412K 0.51% 53
2024
Q4
$3.82M Sell
14,645
-172
-1% -$51K 0.46% 56
2024
Q3
$4.77M Sell
14,817
-681
-4% -$223K 0.65% 39
2024
Q2
$4.84M Sell
15,498
-231
-1% -$67.9K 0.57% 42
2024
Q1
$4.47M Sell
15,729
-5,186
-25% -$1.52M 0.55% 45
2023
Q4
$6.02M Buy
20,915
+1,051
+5% +$286K 0.9% 25
2023
Q3
$5.34M Sell
19,864
-589
-3% -$147K 0.91% 21
2023
Q2
$4.54M Buy
20,453
+24
+0.1% +$5.57K 0.88% 29
2023
Q1
$4.94M Sell
20,429
-364
-2% -$89.4K 1.04% 16
2022
Q4
$5.46M Buy
20,793
+1,255
+6% +$336K 1.11% 22
2022
Q3
$4.4M Sell
19,538
-103
-0.5% -$25K 0.98% 28
2022
Q2
$4.78M Buy
19,641
+570
+3% +$140K 1.03% 27
2022
Q1
$4.61M Buy
19,071
+675
+4% +$155K 0.78% 39
2021
Q4
$4.14M Sell
18,396
-773
-4% -$163K 0.6% 59
2021
Q3
$4.08M Sell
19,169
-282
-1% -$64.9K 0.61% 55
2021
Q2
$4.74M Buy
19,451
+897
+5% +$221K 0.72% 44
2021
Q1
$4.62M Sell
18,554
-197
-1% -$47K 0.83% 37
2020
Q4
$4.31M Sell
18,751
-645
-3% -$149K 0.78% 42
2020
Q3
$4.93M Sell
19,396
-332
-2% -$82.2K 1.08% 29
2020
Q2
$4.65M Sell
19,728
-336
-2% -$76.7K 1.11% 25
2020
Q1
$4.07M Sell
20,064
-794
-4% -$173K 0.96% 23
2019
Q4
$5.03M Sell
20,858
-590
-3% -$130K 0.81% 36
2019
Q3
$4.15M Buy
21,448
+455
+2% +$87.3K 0.69% 36
2019
Q2
$3.87M Sell
20,993
-112
-0.5% -$20.1K 0.6% 42
2019
Q1
$4.01M Sell
21,105
-675
-3% -$129K 0.62% 39
2018
Q4
$4.24M Sell
21,780
-676
-3% -$132K 0.72% 26
2018
Q3
$4.66M Sell
22,456
-720
-3% -$142K 0.6% 45
2018
Q2
$4.28M Buy
23,176
+353
+2% +$62.4K 0.6% 42
2018
Q1
$3.89M Buy
22,823
+617
+3% +$113K 0.59% 40
2017
Q4
$3.86M Sell
22,206
-3,794
-15% -$671K 0.72% 37
2017
Q3
$4.85M Sell
26,000
-12,500
-32% -$2.21M 0.94% 30
2017
Q2
$6.63M Sell
38,500
-2,500
-6% -$407K 0.99% 22
2017
Q1
$6.73M Sell
41,000
-1,200
-3% -$199K 0.98% 26
2016
Q4
$6.17M Sell
42,200
-2,801
-6% -$422K 1.02% 22
2016
Q3
$7.51M Sell
45,001
-678
-1% -$115K 1.07% 32
2016
Q2
$6.95M Buy
45,679
+1,278
+3% +$199K 1.04% 41
2016
Q1
$6.66M Buy
44,401
+2,497
+6% +$371K 0.86% 41
2015
Q4
$6.8M Sell
41,904
-450
-1% -$70.7K 0.75% 41
2015
Q3
$5.86M Buy
42,354
+821
+2% +$129K 0.59% 42
2015
Q2
$6.38M Buy
41,533
+5,872
+16% +$941K 0.56% 34
2015
Q1
$5.7M Buy
35,661
+2,092
+6% +$329K 0.52% 33
2014
Q4
$5.35M Buy
33,569
+3,532
+12% +$550K 0.27% 38
2014
Q3
$4.22M Buy
30,037
+2,078
+7% +$271K 0.21% 38
2014
Q2
$3.31M Sell
27,959
-262,403
-90% -$30.4M 0.15% 45
2014
Q1
$35.8M Sell
290,362
-12,780
-4% -$1.55M 1.67% 34
2013
Q4
$34.6M Sell
303,142
-21,645
-7% -$2.46M 1.56% 36
2013
Q3
$36.4M Sell
324,787
-8,810
-3% -$955K 1.07% 51
2013
Q2
$32.9M Buy
+333,597
New +$34.6M 1.57% 34

Other funds holding AMGN

Navellier & Associates's AMGN Position: Q1 2026 in Review

Navellier & Associates reduced its Amgen (AMGN) stake by 3.8% in Q1 2026, selling an estimated $166K and leaving 11,971 shares worth $4.21M. The position accounts for 0.44% of the portfolio, ranked #53.

Navellier & Associates first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $36.4M in Q3 2013. 3,131 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Navellier & Associates held 11,971 shares of Amgen worth $4.21M as of Q1 2026.
  • Navellier & Associates sold 467 Amgen shares in Q1 2026, an estimated $166K.
  • Amgen made up 0.44% of Navellier & Associates's portfolio in Q1 2026, its #53 holding.
  • Navellier & Associates first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
  • Navellier & Associates's Amgen position peaked at $36.4M in Q3 2013.
  • 3,131 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Navellier & Associates's 13F filing for Q1 2026, filed 7 May 2026.